Adicet Bio, Inc. (ACET) research
Adicet Bio, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $6.47
- As of
Kresmion compiles this page from ACET's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Adicet Bio, Inc. (ACET): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
As of . Source: SEC EDGAR filings for ACET. Method and limitations.
Share the ACET intelligence card
See the full ACET dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ACET on one page. Preview it with sample data, then open it live with a free account.
Preview the ACET dossierActive signals for ACET
- highCONSENSUS_BUY
3 tracked funds increased ACET this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 79% of ACET (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +301% to ACET (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 90% of ACET (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +125% to ACET (2026Q2)
FREE, NO ACCOUNT
Every signal on ACET, as it fires
You are seeing 5 of 8 signals recorded on ACET since 2026-06-21.
The five above landed across 2 days. The other 3 were recorded on 2 other days. 5 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ACET (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 007002207 · 2026Q2 | $3.7M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 007002207 · 2026Q2 | $2.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 007002207 · 2026Q2 | $837K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ACET
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ACET against its peers
ACET's return on equity of -73.4% ranks in the 60th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | ACET | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 1.1M | n/a | 15 |
| Operating margin | n/a | -171.0% | n/a | 12 |
| Net margin | n/a | -212.7% | n/a | 12 |
| Return on equity | -73.4% | -100.8% | 60 | 20 |
Peers (23): AURX, BOLD, XLO, MREO, ANVS, CNTB, ATHE, INKT, KLRS, GUTS, HYPD, XBIT, RNXT, IBIO, HRTX, CELU, FBIO, PDSB, CSBR, EXOZ, RNTX, SPRO, ALDX. Left out: HYFT (period gap), APLM (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ACET: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ACET on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ACET for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.